Philips Healthcare parent Royal Philips Electronics said that it is leading a European consortium to develop MRI- and ultrasound-guided drug delivery technologies for treating cancer and cardiovascular disease.
The project, called SonoDrugs, will aim to develop technologies that deliver drugs to disease sites via the patient's bloodstream, then activate them by focused ultrasound pulses, according to Philips of Eindhoven, Netherlands. SonoDrugs includes 15 industrial partners, university medical centers, and academic institutions in the European Union, and will run for four years. It has a budget of 15.9 million euros ($21 million).
SonoDrugs consortium participants include Philips; nanomedicine firm Nanobiotix of Paris; Lipoid of Ludwigshafen, Germany; Erasmus Medical Center in Rotterdam, Netherlands; University Hospital Münster in Germany; the University of Cyprus in Nicosia, Cyprus; the University of Gent in Belgium; the University of Helsinki in Finland; the University of London in the U.K.; the University of Tours in France; the University Victor Segalen Bordeaux in France; the University of Technology Eindhoven in the Netherlands; and the University of Udine in Italy.
Related Reading
Philips debuts new ultrasound scanner, January 26, 2009
Philips to collaborate with Bard, January 15, 2009
Philips names new CMO, November 30, 2008
Philips Healthcare cuts jobs by 5%, November 21, 2008
Philips teams with NeuroNexus, November 17, 2008
Copyright © 2009 AuntMinnie.com
